A randomized, double-blind, placebo-controlled, multi-center study comparing the efficacy and safety of PMI-150 (intranasal ketamine) to placebo as an analgesic for the treatment of breakthrough pain in cancer patients.
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Ketamine (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- 10 Jan 2012 Actual patient number (2) added as reported by ClinicalTrials.gov.
- 10 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 25 Feb 2011 Planned end date changed from 1 Jun 2009 to 1 Aug 2011 as reported by ClinicalTrials.gov.